Cervical Cancer Treatment Market Size, Share, Growth, Trends, and Global Industry Analysis: By Type (Squamous Cell Carcinoma, Adenocarcinoma, Adenosquamous Carcinoma, Other Types) By Treatment (Radiation Therapy, Chemotherapy, Targeted Therapy, Immunotherapy) By End-use (Hospital & Clinics, Ambulatory Surgery Centers) and Region Forecast 2020-2031

Cervical Cancer Treatment Market size was valued at US$ 8.6 billion in 2024 and is expected to reach US$ 12.4 billion by 2031, growing at a significant CAGR of 5.4% from 2025-2031.  The market is the global industry involved in the medical interventions intended to manage and eliminate cervical cancer a malignancy that occurs in the cervix, which is the lower part of the uterus. Treatment for cervical cancer market is supported by the growing global incidence of cervical cancer, growing awareness for early diagnosis by screening programs, and the growing prevalence of HPV vaccination. Technological developments in targeted therapies as well as immunotherapies with supportive government policies and funding further accelerate the growth of the market.

However, the market is constrained by few access to advanced treatment in low- and middle-income countries, high-cost treatment, and lack of awareness or cultural taboo in certain parts of the world. Also, delayed early diagnosis and healthcare facility inequality continue to constrain timely and proper treatment administration.

Facts & Figures

• Cervical cancer is most often diagnosed between the ages of 35 and 44.
• The average age of diagnosis in the US is 50.
• Over 20% of cervical cancers are diagnosed after age 65.
• It is rare for people younger than 20 to develop cervical cancer.
• Over the past two decades, the majority of countries in the 7MM have experienced a decrease in cervical cancer cases.
• In the United States, incidence rates showed a decline from the mid-1970s to the mid-2000s, attributed in part to increased screening efforts. However, an analysis of SEER data revealed a rise in cases in 2021 following the COVID-19 pandemic, which later returned to a declining trend.
• In the EU4 and the UK, most nations observed a gradual decrease, though Spain and the UK saw relatively stable numbers over the past decade. Despite being a latecomer to HPV vaccination, Japan reported fewer cases in 2023 compared to 2020. While vaccination resumed in November 2021, it remains to be seen whether a significant decline in numbers will occur in the future.

Key Developments

• In February 2024, Pfizer and Genmab announced that the European Medicines Agency (EMA) validated tisotumab vedotin’s marketing authorization application for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after first-line therapy.
• In January 2024, Merck announced that the United States Food andDrug Administration (US FDA) approved KEYTRUDA combinationwith chemoradiotherapy (CRT) for the treatment of patients withFIGO (International Federation of Gynecology and Obstetrics) 2014Stage III–IVA cervical cancer. The approval is based on data fromthe Phase III KEYNOTE-A18 trial.
• In September 2023, Nykode Therapeutics announced the US FDA approval of its Investigational New Drug (IND) application for the Phase II clinical trial of VB10.16, for HPV16-positive cancers, in combination with Roche’s PD-L1 inhibitor atezolizumab in patients with HPV16-positive, PD-L1-positive, recurrent or metastatic cervical cancer.

Cervical Cancer Treatment Market Segmentation

Based on the type

• Squamous Cell Carcinoma
• Adenocarcinoma
• Adenosquamous Carcinoma
• Other Types

Squamous cell carcinoma type of the disease had the largest market share and accounted for the highest revenue. Chronic infection with human papillomavirus (HPV) types 16 and 18, which cause the majority of cases, is the growth reason. Furthermore, in low- and middle-income countries, restricted access to HPV vaccine, screening, and treatment contributes to the burden. Besides, socioeconomic determinants like poverty and gender inequality also contribute to the inequalities in cervical cancer control and prevention.

Based on the treatment

• Radiation Therapy
• Chemotherapy
• Targeted Therapy
• Immunotherapy

Chemotherapy treatment dominated the market and held the highest revenue share. This is due to the improvement in drug development, which has increased the treatment options for cervical adenocarcinoma considerably. Moreover, greater investments in healthcare organizations have enhanced general treatment processes and access. Also, there is an increasing trend towards individualized treatment methods, centering on customized medicinal treatments for patients.

Based on the end use

• Hospitals & Clinics
• Ambulatory Surgery Centers
• Others

Hospitals & clinics segment led the market and generated the highest revenue share. The growth is due to the improved delivery processes in hospitals & clinics with treatments like targeted therapy, radiation therapy, immunotherapy, minimally invasive procedures, and numerous other treatments. In addition, government programs and healthcare policies to enhance the quality of treatment in hospitals & clinics are contributing to the market growth extensively.